Infectious disease
A study conducted by 23andMe and published in Nature Genetics identified a genetic risk factor tied to the loss of smell from COVID-19.
Moderna is poised to commercialize its COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against the RSV.
Studies are ongoing in Israel on whether a fourth dose of an mRNA vaccine offers additional protection. Although the data is still early, it suggests that it might not.
While many of these scams targeted the public at large, scammers also turned their sights to those sources that would naturally be on the spot as the result of demand.
As the COVID-19 pandemic moves into its third year, at least some people think we might be seeing the light at the end of the tunnel as the disease progresses from a pandemic to an endemic stage.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
Researchers from the Medical University of Bialystok in Poland identified a gene that appears to double the risk of severe COVID-19.
Vaccine development is experiencing a resurgence in the wake of the COVID-19 pandemic, with companies developing a variety of approaches.
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
PRESS RELEASES